文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

罗米司亭与艾曲泊帕治疗Wiskott-Aldrich综合征患者血小板减少症的疗效与安全性

Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott-Aldrich syndrome patients.
PubMed 文献 · Br J Haematol · 2025-05-21

这项前瞻性试验纳入28例0-17岁Wiskott-Aldrich综合征患者,接受血小板生成素受体激动剂治疗,比较罗米司亭与艾曲泊帕的疗效与安全性及换药获益。罗米司亭总体血小板反应概率73%,艾曲泊帕43%;换用另一种药物后,换用艾曲泊帕者33%达完全血小板反应,启用罗米司亭者43%达完全反应;TPO-RA累积疗效87%。艾曲泊帕相关不良事件包括1例2级和1例4级严重不良事件(可逆性急性肝衰竭伴代谢性酸中毒和脑病)。

要点

  • 罗米司亭总体血小板反应概率73%,艾曲泊帕为43%。
  • 换用替代TPO-RA后,换用艾曲泊帕者33%、启用罗米司亭者43%达完全血小板反应。
  • TPO-RA累积疗效为87%。

核心结论

  • 罗米司亭与艾曲泊帕均对Wiskott-Aldrich综合征患者的血小板减少症有效,TPO-RAs被证明是等待干细胞移植或选择保守治疗患者的有效治疗。

研究设计与样本

  • 前瞻性试验,纳入28例0-17岁Wiskott-Aldrich综合征患者,接受血小板生成素受体激动剂(TPO-RAs)治疗,评估罗米司亭与艾曲泊帕的比较疗效与安全性及个体换药获益。

主要发现

  • 总体血小板反应(完全反应为血小板计数≥100×10⁹/L,部分反应为血小板计数较基线升高≥30×10⁹/L)概率:罗米司亭73%,艾曲泊帕43%。
  • 换用替代TPO-RA后达到完全血小板反应:换用艾曲泊帕者33%,启用罗米司亭者43%。
  • TPO-RAs累积疗效(考虑替代治疗)为87%。
  • 艾曲泊帕相关不良事件:1例2级不良事件和1例4级严重不良事件,为可逆性急性肝衰竭伴代谢性酸中毒和脑病。

关键数值与推荐

  • 完全反应定义为血小板计数≥100×10⁹/L;部分反应定义为血小板计数较基线升高≥30×10⁹/L。
  • 总体血小板反应概率:罗米司亭73%,艾曲泊帕43%。
  • 换药后完全血小板反应:换用艾曲泊帕者33%,启用罗米司亭者43%。
  • TPO-RAs累积疗效为87%。

临床怎么用

  • 原文结论指出TPO-RAs是等待干细胞移植或选择保守治疗的WAS患者的有效治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wiskott-Aldrich syndrome (WAS) is a life-threatening inborn error of immunity associated with bleeding risk due to profound thrombocytopenia. We previously demonstrated that romiplostim is effective for thrombocytopenia treatment in 60% of WAS patients. In this prospective trial, 28 WAS patients (aged 0-17 years) were treated with thrombopoietin receptor agonists (TPO-RAs) to evaluate the comparative efficacy and safety of romiplostim versus eltrombopag and to assess the benefit of switching these molecules in individual subjects. We demonstrate that both drugs are effective, with the probability of achieving an overall platelet response (complete response-platelet count of 100 × 109/L or more and partial response-platelet count increase of 30 × 109/L or higher above baseline) of 73% for romiplostim and 43% for eltrombopag. Switching to an alternative TPO-RA allowed the achievement of a complete platelet response in 33% of patients after switching to eltrombopag and in 43% after romiplostim initiation. The cumulative efficacy of TPO-RAs, taking into account alternative therapy, was 87%. There was a grade 2 adverse event (AE) and a severe grade 4 AE related to eltrombopag-reversible acute liver failure associated with metabolic acidosis and encephalopathy. TPO-RAs proved to be an effective treatment for WAS patients waiting for stem cell transplantation or opting for a conservative treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ogneva A, Rodina Y, Pershin D, et al. Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott-Aldrich syndrome patients. Br J Haematol. 2025. PMID: 40400288. doi:10.1111/bjh.20182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。